Biotech, and pathogen resistance

Diseased leaves from a potato late-blight field trial (source: Jonathan Jones).

Plant pathogens cause global crop losses of 15% every year, and are managed either by the use of resistant varieties or by pesticides. A trio of papers from The Sainsbury lab in the UK provides evidence that biotech approaches to engineering pathogen resistance could underpin sustainable genetic solutions to crop pests and pathogens. In one report, soybean is made resistant to Asian soybean rust using a gene cloned from the orphan legume pigeonpea. This finding is notable because Asian soybean rust resistance is absent from all commercially grown soybean lines. Plus, finding disease resistance genes that work in soybean in pigeonpea means that legumes could contain a reservoir of pathogen-resistance genes. In two accompanying reports, resistance genes for potato late-blight and wheat stem rust were identified by developing rapid resistance-gene cloning methods.

This research was funded in part by the 2Blades Foundation.

A Cassava Genome Resource

Cassava

Cassava root from Uganda with necrotic brown lesions, characteristic of Cassava Brown Streak Disease.(source: Steve Rounsley, Dow AgriSciences)

Cassava is an important (but poorly performing) staple crop in Africa and other tropical countries. Although cassava can outcross, most cultivated cassava is clonally propagated, owing in part to long breeding cycles. Cassava is susceptible to disease, but the available germplasm is of limited diversity, so breeders need genomic sources of diversity to improve this vital crop. Daniel Rokhsar (University of California, Berkeley and DOE JGI), Steve Rounsley (Dow Agrosciences) and colleagues sequenced nearly 60 cultivated cassava and wild relatives and genotyped more than 250 African accessions to provide a Cassava genome resource that will support genome-enabled improvement. Their paper can be found here online, and in the coming May issue of Nature Biotechnology.

Chile’s Austral Incuba

 

valdivia_la_nube

Rio Valdivia, cutting through Valdivia, Chile.

Or, why hatch a biotech business?

There are around 20 business incubators in Chile, and for the last couple of years they have been getting kind of a bad reputation. Their main job is to take government grants (usually seed funds) and allocate them to different projects that they scout through competitions and direct application. Many of these incubators base their business models on taking a percentage of their startups’ sales for up to 5 years, or equity up to 7% to be cashed out in 5 years, or a combination of both. Considering this timeline, it will probably come as no surprise that most business incubators here avoid biotech projects like the plague.

Which is why the case of Austral Incuba, arguably the only business incubator to focus in biotech in all of Chile, is so special. How have they managed to survive while competing with IT-based incubators with shorter timelines, lower risks and less capital-intensive projects?

Macarena Sáez, Austral Incuba’s CEO, tells me the choice to focus on bio-based projects was a conscious one, made about six years ago (the incubator has been in existence 11 years). Like every other incubator, they started working with the inevitable app and website groups, and all the projects that make you go “why are you wasting your brainpower in this,” (my words, not hers) until they realized that most of those entrepreneurs seemed much more interested in bettering the state of their personal finances than the state of their country.

But Austral Incuba was different from the start. It is located in Valdivia, a city more than 800 km away from Santiago, the country’s capital, and is housed within Universidad Austral de Chile. The university’s motto, “knowledge and nature,” reflects its environment (it is smack in the middle of forests and rivers) and their academic focus. Their most prestigious Master’s program, in human-scale development and ecological economy, is actually dictated by Manfred Max Nef, who was awarded the Right Livelihood Award in 1982. The downside is that not only is Valdivia far away from Santiago (we are talking a 12-hour bus ride at least), but also the city’s GDP is roughly 4 times smaller than that of Santiago, and still has grave illiteracy and poverty issues. So if incubating a business “from the end of the world,” as we ourselves refer to Chile, seemed hard, trying to do that from the south of said end-of-the-world sounds impossible.

ok3-1030x773

The Austral Incuba team.

“It feels like our very own crusade,” says Macarena. “We know the conditions are unfavorable and yet we choose high-risk projects such as biotech-related ones, because those are the ones that actually respond to what we see in our environment. The impact you can have while developing bio-based projects is infinitely bigger than your classic app or website, and can actually take responsibility for what is happening in our local area, both socially and environmentally speaking.”

Even the entrepreneurs there are different. They bring premises from their scientific disciplines to their startup work. They don’t just want to make a sustainable product; they want to work in creating a sustainable economy, capable of regenerating their local environment and society.

It’s not all butterflies and rainbows, though. The “diva scientist syndrome,” as I like to call it, is quite real and can be a huge impediment to the development of a project. As Macarena puts it, “We understand that you rule the lab but that does not mean you rule the world!” Which is to say that these entrepreneurs might know everything about their science, but sometimes have no idea what a value proposition is. A scientist’s ego might be one of the worst obstacles when becoming entrepreneurs – they can be un-coachable and deaf to feedback. In Chile this “diva scientist” attitude can become even worse when combined with the “rockstar entrepreneur” vibe we all seem to be getting secondhand from Silicon Valley. There are so many entities here that exist solely to serve the entrepreneur, including throwing money at them, that we haven’t been able to create a proper VC structure. This also has hurt the development of the entrepreneurs. We get money all the time, but we don’t get the smarts that should come with it – which is precisely what Austral and other business incubators are trying to solve.

Luckily, Macarena says that trait is more common in an older generation of entrepreneurs and not as prevalent in the younger crops. And it’s these younger ones that have proved themselves worthy of Austral’s help, over and over. “One of our entrepreneurs relocated from Santiago and practically revived a small town that had been left down on its luck by employing tens of people that had been left unemployed after the closing of a local industry. Another is obsessed with creating added value to local industry’s waste, and is now exporting his products to the US and Europe – all while making the region cleaner and greener,” she says.

The experience Austral has had with these entrepreneurs reaffirms their belief that there’s a certain common trait to all scientific entrepreneurs: a spirit of collaboration. “During our first 5 years we witnessed the non-necessity of collaborating that traditional startups put in place through constant outsourcing and extreme secretiveness,” Macarena says. “Bioentrepreneurs are radically different. They are aware of social pain, and that pushes them towards collaboration as a tool to improve social conditions around them.”

Emilia Diaz